<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been regarded as an endogenous inhibitor of LDL-C, and anti-PCSK9 monoclonal antibodies have been used for treating hypercholesterolemia (
 <xref rid="B135" ref-type="bibr">135</xref>, 
 <xref rid="B136" ref-type="bibr">136</xref>). Chan et al. reported the effect of subcutaneous injection of PCSK9 inhibitor with evolocumab for 8 weeks on postprandial TRL in healthy adult men. Evolocumab reduced the total area under the curve VLDL-apoB100 (
 <italic>p</italic> &lt; 0.001), but did not significantly change the kinetics of apoB48 (
 <xref rid="B137" ref-type="bibr">137</xref>).
</p>
